An original study proposed using HER2-targeting 177Lu (trastuzumab-AuNP-177Lu) and nontargeting AuNP-177Lu for killing and tumor inhibition of HER2-overexpressing breast cancer (BC) cells in vitro and proceeded to evaluate the efficacy of trastuzumab-modified AuNPs and compare in vivo proliferation after intratumoral injection [61]. The gene discussed is ERBB2; the disease is breast carcinoma.